3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
14
Active not recruiting
2
Unknown
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
9
Lung Neoplasms
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Leukemia, Myeloid, Acute
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Rectal Neoplasms
3
Melanoma
3
Leukemia
3
Glioblastoma
3
Cholangiocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Gliosarcoma
2
Glioma
2
Congenital Abnormalities
2
Colonic Neoplasms
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stomatitis
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pleural Effusion, Malignant
1
Pain
1
Interventions
Paclitaxel
20
Carboplatin
16
liposomal doxorubicin
10
Bevacizumab
10
Gemcitabine
8
Topotecan
7
Taxes
7
Cisplatin
7
pembrolizumab
6
Doxorubicin
5
Cyclophosphamide
5
Nivolumab
4
fludarabine
3
Oxaliplatin
3
Immunoglobulin G
3
Hyperthermic Intraperitoneal Chemotherapy
3
Disulfides
3
Cytoreduction Surgical Procedures
3
trebananib
2
talazoparib
2
rucaparib
2
peginterferon alfa-2b
2
olaparib
2
fludarabine phosphate
2
aldesleukin
2
Surgical Procedures, Operative
2
STA 9090
2
Platinum
2
Lenalidomide
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Fallopian Tube Neoplasms
×
Drug Therapy
×
Clear all
NCT03642132
2023-04-06
JAVELIN OVARIAN PARP100
Pfizer
Phase 3
Terminated
79 enrolled
18 charts